Attorney Docket No. 5051-337DVCT3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Stomp et al. Application No.: 10/677,441

Filed: October 2, 2003 For: GENETICALLY ENGINEERED DUCKWEED

Confirmation No. 9042 Group Art Unit: 1638 Examiner: Li Zheng

Date: October 7, 2011

Commissioner for Patents Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Attached is an Information Disclosure Statement listing of documents, together with a copy of any listed

Sir:

foreign patent docume	ent and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent
application publicatio	on is not provided herewith in accordance with 37 C.F.R. § 1.98(a)(2)(ii).
	ance with 37 CFR 1.97(b), the Information Disclosure Statement is being filed:
□(1) w	within three months of the filing date of a national application other than a continued
p	rosecution application under §1.53(d);
☐ (2) W	within three months of the date of entry of the national stage as set forth in §1.491 in an
iı	nternational application;
☐(3) b	efore the mailing of a first Office Action on the merits; or
⊠ (4) b	refore the mailing of a first Office Action after the filing of a request for continued
e	examination under §1.114.
☐ In accord	ance with 37 CFR 1.97(c), the Information Disclosure Statement is being filed after the
period specified in 37	CFR 1.97(b) above, but before the mailing date of any of a final action under §1.113, a notice
of allowance under §1	1.311, or an action that otherwise closes prosecution in the application, and is accompanied by
one of the following:	
☐(1) T	The statement specified under 37 CFR 1.97(e), as follows:
	Each item of information contained in the Information Disclosure Statement was first
cited in any communication from a foreign patent office in a counterpart foreign application not	
more than three months prior to the filing of the Information Disclosure Statement; or	
	No item of information contained in the Information Disclosure Statement was cited in
a communication from a foreign patent office in a counterpart foreign application, and, to the	
knowledge of the person signing the certification after making reasonable inquiry, no item of	
information contained in the Information Disclosure Statement was known to any individual	
designated in §1.56(c) more than three months prior to the filing of the Information Disclosure	
State	ment; <u>or</u>
(2) T	The fee set forth in §1.17(p);

Attorney Docket No. 5051-337DVCT3 Application No. 10/677,441 Filed: October 2, 2003 Page 2 of 2 In accordance with 37 CFR 1.97(d), the Information Disclosure Statement is being filed after the period specified in 37 CFR 1.97(c) above, but on or before payment of the issue fee, and is accompanied by both of the following: (1) The statement specified under 37 CFR 1.97(e), as follows: That each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or That no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in \$1.56(c) more than three months prior to the filing of the Information Disclosure Statement: and (2) The fee set forth in §1.17(p); In accordance with 37 CFR 1.97(g), the Information Disclosure Statement shall not be construed as a representation that a search has been made. In accordance with 37 CFR 1,97(h), the Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56(b). The Commissioner is hereby authorized to charge \$180.00 as fee specified in 37 C.F.R. § 1.17(p), and any fee deficiency or credit any overpayment, to Deposit Account No. 50-0220; or No fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220. Respectfully submitted, Bleen. Bonn.

Customer Number 20792 Myers Bigel Sibley & Sajovec, P.A. P.O. Box 37428

Raleigh, NC 27627 Phone: 919-854-1400 Fax: 919-854-1401 CERTIFICATION OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4) to the U.S.

Patent and Trademark Office on October 7, 2011.

Registration No. 57,154

Claire Wimberly